Wigan Today (KC) 22-Aug-08

From Kidney Cancer Resource

Jump to: navigation, search

Go Back To Wigan Today (KC)

Cancer patients lose out in postcode lottery

Cancer patients across Wigan are being denied new drugs in a recently exposed county-wide postcode lottery. Health bosses responsible for approving new drugs for patients in Wigan have rejected around a third of the requests they have received for new kidney, bowel and blood cancer drugs in the last two years.

Altogether, half of the applications for new cancer drugs have been approved by the Ashton, Wigan and Leigh Primary Care Trust. The drugs in question have been licensed for use but not approved by the National Institute of Clinical Excellence, meaning they are not widely available on the NHS,

They include Sutent, a kidney cancer drug that NICE has just ruled is too expensive for the NHS. Dr Mark Saunders, a bowel cancer specialist at the Christie Hospital in Manchester conducted the study.

He said: "Patients with cancer should not have to go through the trauma, stress and delay of appealing for access to treatment that ought to be available as a matter of course.

"They already have enough to deal with in terms of coping with the trauma of a terminal illness. You really cannot put a value on the extra time and quality of life these drugs can provide.

"If other European countries are able to provide them, then why can't we do the same?" Patients across other parts of Greater Manchester are missing out on new drugs depending on where they live.

In Manchester, six-out-of-seven people who applied for pioneering new drugs were turned down. But Bolton, Bury, Oldham, Tameside and Rochdale have not rejected any of the applications they have received in the last two years, research by a cancer expert shows.

Most of the requests are for the kidney cancer treatment Sutent. Wigan, Salford and Stockport primary care trusts all turned down at least a third of the applications for new kidney, bowel and blood cancer drugs.

Difficulty arises when new drugs, which are often expensive, are licensed for general use but are not approved for funding by the government.

A spokesman for AWLPCT said: "In lieu of NICE Guidance, the PCT would review decisions made by the Scottish Medicines Consortium. If not reviewed there, the PCT will look for guidelines developed by recognised national expert groups and accepted nationally.

"If there is no national guidance, then the PCT would consider the evidence provided with the application for funding. Applications are treated the same, irrespective of whether received from a patient or a consultant.

"Any application must, however, be supported by unbiased clinical evidence, detailing that patient's specific condition, the previous treatments/responses, adverse effects etc. It must also provide a very clear clinical view on the expected benefits of treatment for that patient.

"If the application is for exceptional circumstances, then the application must demonstrate why that patient is different from the usual population that might be treated and set out clinical rationale why that patient would respond more successfully to the treatment.

"Individual decisions are based upon clinical effectiveness and expected treatment outcomes. "This must be supported by published clinical evidence."

To View The Original Article Click Here

Convert This Page to PDF format

Disclaimer

Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.

E&OE - Errors & Omissions Excepted

As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.

Personal tools